Patents by Inventor Carine Chevrier

Carine Chevrier has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11292788
    Abstract: The present invention relates to compounds of the general formula (I), and the pharmaceutically acceptable salts and solvates thereof, wherein Ar, Z and Y are as described herein and R1 is a group of the structure wherein n is 0 or 1; R2 is H, deuterium or methyl; R3 is methyl, trifluoromethyl, ethyl, or taken with R2 together forms a cyclopropyl group, or R3 forms a methylene bridge to the carbon atom marked *, which are suitable for the treatment of autoimmune diseases and chronic inflammation.
    Type: Grant
    Filed: September 6, 2018
    Date of Patent: April 5, 2022
    Assignee: Immunic AG
    Inventors: Jakob Felding, Hella Kohlhof, Manfred Groppel, Rolf Andreas Muhler, Daniel Vitt, Carine Chevrier, Mirko Zaja, Stefan Tasler
  • Publication number: 20210061796
    Abstract: The present invention relates to compounds of the general formula (I), and the pharmaceutically acceptable salts and solvates thereof, wherein Ar, Z and Y are as described herein and R1 is a group of the structure wherein n is 0 or 1; R2 is H, deuterium or methyl; R3 is methyl, trifluoromethyl, ethyl, or taken with R2 together forms a cyclopropyl group, or R3 forms a methylene bridge to the carbon atom marked *, which are suitable for the treatment of autoimmune diseases and chronic inflammation.
    Type: Application
    Filed: September 6, 2018
    Publication date: March 4, 2021
    Applicant: Immunic AG
    Inventors: Jakob FELDING, Hella KOHLHOF, Manfred GROPPEL, Rolf Andreas MUHLER, Daniel VITT, Carine CHEVRIER, Mirko ZAJA, Stefan TASLER
  • Patent number: 8592456
    Abstract: The present invention relates to compounds of the general formula (I), and the pharmaceutically acceptable salt or solvate thereof, as anti-inflammatory and immunomodulatory agents.
    Type: Grant
    Filed: January 27, 2012
    Date of Patent: November 26, 2013
    Assignee: 4SC Discovery GmbH
    Inventors: Johann Leban, Stefan Tasler, Roland Baumgartner, Wael Saeb, Carine Chevrier
  • Patent number: 8354436
    Abstract: The present invention relates to compounds of the general formula (I), and the pharmaceutically acceptable salt or solvate thereof, as anti-inflammatory and immunomodulatory agents.
    Type: Grant
    Filed: January 27, 2012
    Date of Patent: January 15, 2013
    Assignee: 4SC Discovery GmbH
    Inventors: Johann Leban, Stefan Tasler, Wael Saeb, Carine Chevrier
  • Publication number: 20120196861
    Abstract: The present invention relates to compounds of the general formula (I), and the pharmaceutically acceptable salt or solvate thereof, as anti-inflammatory and immunomodulatory agents.
    Type: Application
    Filed: January 27, 2012
    Publication date: August 2, 2012
    Applicant: 4SC Discovery GmbH
    Inventors: Johann LEBAN, Stefan TASLER, Roland BAUMGARTNER, Wael SAEB, Carine CHEVRIER
  • Publication number: 20120196862
    Abstract: The present invention relates to compounds of the general formula (I), and the pharmaceutically acceptable salt or solvate thereof, as anti-inflammatory and immunomodulatory agents.
    Type: Application
    Filed: January 27, 2012
    Publication date: August 2, 2012
    Applicant: 4SC Discovery GmbH
    Inventors: Johann LEBAN, Stefan TASLER, Wael SAEB, Carine CHEVRIER
  • Publication number: 20100249102
    Abstract: The present invention relates generally to azatriocyclic containing pharmaceutical agents, and in particular, to azatricyclic metalloprotease inhibiting compounds. More particularly, the present invention provides a new class of azatricyclic MMP-3, MMP-8 and/or MMP-13 inhibiting compounds, that exhibit an increased potency and selectivity in relation to currently known MMP-13, MMP-8 and MMP-3 inhibitors.
    Type: Application
    Filed: April 6, 2010
    Publication date: September 30, 2010
    Applicant: ALANTOS PHARMACEUTICALS HOLDINGS, INC.
    Inventors: Christian Gege, Carine Chevrier, Matthias Schneider, Harald Bluhm, Matthias Hochgürtel, Hongbo Deng, Brian M. Gallagher, JR., Irving Sucholeiki, Arthur Taveras
  • Patent number: 7749996
    Abstract: The present invention relates generally to azatriocyclic containing pharmaceutical agents, and in particular, to azatricyclic metalloprotease inhibiting compounds. More particularly, the present invention provides a new class of azatricyclic MMP-3, MMP-8 and/or MMP-13 inhibiting compounds, that exhibit an increased potency and selectivity in relation to currently known MMP-13, MMP-8 and MMP-3 inhibitors.
    Type: Grant
    Filed: November 20, 2007
    Date of Patent: July 6, 2010
    Assignee: Alantos Pharmaceutical Holdings, Inc.
    Inventors: Christian Gege, Carine Chevrier, Matthias Schneider, Harald Bluhm, Matthias Hochgürtel, Hongbo Deng, Brian M. Gallagher, Jr., Irving Sucholeiki, Arthur Taveras
  • Patent number: 7713966
    Abstract: The present invention relates generally to azabicyclic containing pharmaceutical agents, and in particular, to azabicyclic metalloprotease inhibiting compounds. More particularly, the present invention provides a new class of azabicyclic MMP-3, MMP-8 and/or MMP-13 inhibiting compounds, which exhibit an increased potency and selectivity in relation to currently known MMP-13, MMP-8 and MMP-3 inhibitors.
    Type: Grant
    Filed: November 20, 2007
    Date of Patent: May 11, 2010
    Assignee: Alantos Pharmaceuticals Holding, Inc.
    Inventors: Christian Gege, Matthias Schneider, Carine Chevrier, Hongbo Deng, Irving Sucholeiki, Brian M. Gallagher, Jr., Michael Bosies, Christoph Steeneck, Xinyuan Wu, Matthias Hochgürtel, Bert Nolte, Arthur Taveras
  • Publication number: 20100087420
    Abstract: The present invention relates generally to azatriocyclic containing pharmaceutical agents, and in particular, to azatricyclic metalloprotease inhibiting compounds. More particularly, the present invention provides a new class of azatricyclic MMP-3, MMP-8 and/or MMP-13 inhibiting compounds, that exhibit an increased potency and selectivity in relation to currently known MMP-13, MMP-8 and MMP-3 inhibitors.
    Type: Application
    Filed: December 4, 2009
    Publication date: April 8, 2010
    Applicant: ALANTOS PHARMACEUTICALS HOLDINGS, INC.
    Inventors: Christian Gege, Carine Chevrier, Matthias Schneider, Harald Bluhm, Matthias Hochgürtel, Hongbo Deng, Brian M. Gallagher, JR., Irving Sucholeiki, Arthur G. Taveras
  • Publication number: 20080261968
    Abstract: The present invention relates generally to azabicyclic containing pharmaceutical agents, and in particular, to azabicyclic metalloprotease inhibiting compounds. More particularly, the present invention provides a new class of azabicyclic MMP-3, MMP-8 and/or MMP-13 inhibiting compounds, which exhibit an increased potency and selectivity in relation to currently known MMP-13, MMP-8 and MMP-3 inhibitors.
    Type: Application
    Filed: November 20, 2007
    Publication date: October 23, 2008
    Inventors: Christian Gege, Matthias Schneider, Carine Chevrier, Hongbo Deng, Irving Sucholeiki, Brian M. Gallagher, Michael Bosies, Christoph Steeneck, Xinyuan Wu, Matthias Hochgurtel, Bert Nolte, Arthur Taveras
  • Publication number: 20080221128
    Abstract: The present invention relates generally to pharmaceutical agents containing a heterocyclic moiety, and in particular, to heterocyclic metalloprotease inhibiting compounds. More particularly, the present invention provides a new class of heterocyclic MMP-3, MMP-8 and/or MMP-13 inhibiting compounds with a squaramide or benzoxazinone moiety, that exhibit an increased potency and selectivity in relation to currently known MMP-13, MMP-8 and MMP-3 inhibitors.
    Type: Application
    Filed: March 7, 2008
    Publication date: September 11, 2008
    Inventors: Christian Gege, Carine Chevrier, Brian M. Gallagher, Arthur Taveras
  • Publication number: 20080221093
    Abstract: The present invention relates generally to pharmaceutical agents containing a heterocyclic moiety, and in particular, to heterocyclic metalloprotease inhibiting compounds. More particularly, the present invention provides a new class of heterocyclic MMP-13 inhibiting compounds with a benzoxazinone moiety, that exhibit an increased potency and selectivity in relation to currently known MMP-13 inhibitors.
    Type: Application
    Filed: March 7, 2008
    Publication date: September 11, 2008
    Inventors: Christian Gege, Harald Bluhm, Matthias Hochgurtel, Matthias Schneider, Carine Chevrier, Arthur Taveras
  • Publication number: 20080221095
    Abstract: The present invention relates generally to pharmaceutical agents containing a heterocyclic moiety, and in particular, to heterocyclic metalloprotease inhibiting compounds. More particularly, the present invention provides a new class of heterocyclic MMP-3, MMP-8 and/or MMP-13 inhibiting compounds with a squaramide or benzoxazinone moiety, that exhibit an increased potency and selectivity in relation to currently known MMP-13, MMP-8 and MMP-3 inhibitors.
    Type: Application
    Filed: March 7, 2008
    Publication date: September 11, 2008
    Inventors: Christian Gege, Carine Chevrier, Brian M. Gallagher, Arthur Taveras
  • Publication number: 20080207607
    Abstract: The present invention relates generally to azatriocyclic containing pharmaceutical agents, and in particular, to azatricyclic metalloprotease inhibiting compounds. More particularly, the present invention provides a new class of azatricyclic MMP-3, MMP-8 and/or MMP-13 inhibiting compounds, that exhibit an increased potency and selectivity in relation to currently known MMP-13, MMP-8 and MMP-3 inhibitors.
    Type: Application
    Filed: November 20, 2007
    Publication date: August 28, 2008
    Inventors: Christian Gege, Carine Chevrier, Matthias Schneider, Harald Bluhm, Matthias Hochgurtel, Hongbo Deng, Brian M. Gallagher, Irving Sucholeiki, Arthur Taveras